Cholangiocarcinoma Excellence Forum

Cholangiocarcinoma

Excellence Forum

Videos

Outcomes of Liver Transplantation for Perihilar Cholangiocarcinoma: New Standard of Care?

11/23/2022

Julie Heimbach, MD, discusses a benchmark study that investigated outcomes of patients who received neoadjuvant chemoradiotherapy followed by liver transplantation for perihilar cholangiocarcinoma.

Julie Heimbach, MD, discusses a...

11/23/2022

Oncology

TIm Pawlik, MD, PhD, MPH, Wexner Medical Center

Videos

Researchers Develop Dynamic Prognostic Model for Patients With Intrahepatic Cholangiocarcinoma Undergoing Curative Resection

11/16/2022

Tim Pawlik, MD, explains how he and colleagues used landmark analysis to develop a prognostic model that provides a more dynamic prediction of long-term outcomes for patients undergoing curative-intent surgery for intrahepatic...

Tim Pawlik, MD, explains how he...

11/16/2022

Oncology

Lipika Goyal, MD, Stanford Cancer Center

Videos

Futibatinib Receives FDA Approval for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions and Rearrangements

10/31/2022

Lipika Goyal, MD, shares her insight about the recent FDA approval of futibatinib for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements and discusses findings from the FOENIX-CCA2 trial, which led to the approval.

Lipika Goyal, MD, shares her...

10/31/2022

Oncology

Quiz

True or False: In the phase 2 FIDES-01 study, derazantinib was found to have a comparable toxicity profile to other FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib.

10/21/2022

In the phase 2 FIDES-01 study, was derazantinib found to have a comparable toxicity profile to other small molecule, FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib?

In the phase 2 FIDES-01 study,...

10/21/2022

Oncology

Mitesh Borad, MD, Mayo Clinic Cancer Center

Videos

Derazantinib Demonstrates Efficacy, Tolerability for Intrahepatic Cholangiocarcinoma With FGFR2 Aberrations

10/17/2022

Mitesh Borad, MD, reviews results from a pivotal phase 2 trial investigating derazantinib in chemotherapy-exposed patients with intrahepatic cholangiocarcinoma and FGFR2 fusions, mutations, or amplifications.

Mitesh Borad, MD, reviews...

10/17/2022

Oncology

Quiz

Quiz: Durvalumab Added to Gemcitabine-Cisplatin for Biliary Tract Cancers

09/02/2022

In the TOPAZ-1 trial which determined whether the addition of durvalumab to gemcitabine-cisplatin chemotherapy conferred a survival benefit for patients with advanced or metastatic biliary tract cancers, which primary tumor location saw...

In the TOPAZ-1 trial which...

09/02/2022

Oncology

Rachna Schroff, MD, University of Arizona Cancer Center

Videos

Developments in Novel and Targeted Therapies for Biliary Tract Cancers

09/01/2022

Rachna Shroff, MD, highlights recent developments in the treatment of cholangiocarcinoma, including updates in novel and targeted therapies, during her presentation at the Great Debates and Updates in Gastrointestinal Malignancies meeting.

Rachna Shroff, MD, highlights...

09/01/2022

Oncology

Podcasts

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma

07/29/2022

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Margherita Rimini, MD, discusses...

07/29/2022

Oncology

Ruth He, MD, Lombardi Comprehensive Cancer Center

Podcasts

Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

07/22/2022

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Ruth He, MD, discusses findings...

07/22/2022

Oncology

Arndt Vogel, MD, Hannover Medical School

Podcasts

Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

07/14/2022

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Arndt Vogel, MD, shares results...

07/14/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology